Form 8-K RESMED INC For: Jan 23

Go back to Form 8-K RESMED INC For: Jan 23

JPMorgan Upgrades ResMed (RMD) to Overweight

January 24, 2017 7:56 AM EST

JPMorgan upgraded ResMed (NYSE: RMD) from Neutral to Overweight with a price target of $72.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $63.60 yesterday.

... More